Exalenz reports trial success for breath test bacteria detector
The company aims to obtain FDA approval for its device.
Exalenz, among whose shareholders are Moshe (Mori) Arkin and Hadasit, the technology transfer company of Hadassah Hospital, carried out the trial among 167 patients, and obtained a 99.2% degree of accuracy in the results.
Exalenz CEO Steven Eitan said, "The trial results and its impressive success represent an important milestone in the company's business strategy. In addition, the results and the use of the new model considerably enlarge the company's potential market of H. pylori examinations. We believe that a market segment has opened up for us of tests in central laboratories that the company intends to set up. We believe that revenue from this sales model will amount to millions of dollars in 2010."
Published by Globes [online], Israel business news - www.globes-online.com - on December 13, 2009
© Copyright of Globes Publisher Itonut (1983) Ltd. 2009
- Tel Aviv market report
- Tel Aviv Stock Exchange
- Israeli stocks in NY
- Arbitrage gaps for dual-listed stocks
- Israeli stocks in Europe
- Israeli stocks on other markets
- Tel Aviv 25 options
- Mutual funds
- Current representative shekel rates
- Historical representative shekel rates
- Bank shekel rates
- Shekel/dollar options